Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epirubicin SCHEMBL12349863 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL1501770 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21184881 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL14227487 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL24421866 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL14562311 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL23365786 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22403027 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21914951 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22291815 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 359074 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187782-B2 | PDL1 peptides for use in cancer vaccines | IO BIOTECH APS (DK) | 2025-01-07 | — | — | US | claimed |
| CN-119256419-A | Polymer solid electrolyte and preparation method thereof | 株式会社LG新能源 | 2025-01-03 | — | — | CN | claimed |
| US-20250000997-A1 | METHOD FOR IMPROVING QUALITY OF ANTIBODY-DRUG CONJUGATE PRODUCT | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-01-02 | — | — | US | claimed |
| CN-119215173-A | Application of AVEN as target in preparing medicine for treating doxorubicin cardiomyopathy | 复旦大学附属中山医院 | 2024-12-31 | — | — | CN | claimed |
| US-12178885-B2 | Method for mediating targeted delivery of a composition to the brain of a subject in need thereof | FUDAN UNIVERSITY (CN) | 2024-12-31 | — | — | US | claimed |
| CN-119191366-A | Doped magnetic nano particle and preparation method and application thereof | 中国科学院精密测量科学与技术创新研究院 | 2024-12-27 | — | — | CN | claimed |
| CN-119213006-A | Genetic sequence-glycoconjugates for enhanced liver and kidney specific targeting | 康涅狄格大学 | 2024-12-27 | — | — | CN | claimed |
| US-20240423972-A1 | CHEMOTHERAPEUTIC BIOADHESIVE PARTICLES WITH IMMUNOSTIMULATORY MOLECULES FOR CANCER TREATMENT | YALE UNIVERSITY | 2024-12-26 | — | — | US | claimed |
| US-20240425752-A1 | BILIRUBIN-COATED RADIO-LUMINESCENT PARTICLES | PURDUE RESEARCH FOUNDATION (US) | 2024-12-26 | — | — | US | claimed |
| US-20240424118-A1 | VECTORS TARGETING BETA-D-N-ACETYLGLUCOSAMINIDASE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-12-26 | — | — | US | claimed |
| US-4267163-A | CAUSED BY ADRIAMYCIN CYTOSTATS | BIOCARN LIMITED (US) | 1981-05-12 | — | — | US | claimed |
| WO-1981001145-A1 | HYDROLYTIC ENZYME-ACTIVATIBLE PRO-DRUGS | UNIV ILLINOIS (US) | 1981-04-30 | — | — | WO | claimed |
| US-4263279-A | ANTICANCER AGENTS LINKED TO TUMOR-SPECIFIC ANTIBODIES | YEDA RESEARCH & DEVELOPMENT CO. LTD (IL) | 1981-04-21 | — | — | US | claimed |
| US-4263428-A | LINKING TWO ANTIBIOTICS WITH A DIHYDRAZIDE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1981-04-21 | — | — | US | claimed |
| EP-0022515-A1 | Anthracycline glycosides, process for their preparation and therapeutical composition containing them | FARMITALIA CARLO ERBA S.p.A. (IT) | 1981-01-21 | — | — | EP | claimed |
| US-4246399-A | Complexes of doxorubicin exhibiting enhanced stability | INTERX RESEARCH CORPORATION (US) | 1981-01-20 | — | — | US | claimed |
| EP-0010964-A1 | Ravidomycin, process of preparation and pharmaceutical compositions containing same | AYERST, MCKENNA AND HARRISON INC. (CA) | 1980-05-14 | — | — | EP | claimed |
| US-4138480-A | METAL CHELATES USEFUL AS ANTITUMOR AGENTS | GOSALVEZ MARIO | 1979-02-06 | — | — | US | claimed |
| US-4093607-A | ANTITUMOR ANTIBODY, ANTICANCER DRUG | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1978-06-06 | — | — | US | claimed |
| US-4003996-A | Spirolactone for inhibiting the cardiotoxic effects of adriamycin | G. D. SEARLE & CO. (US) | 1977-01-18 | — | — | US | claimed |